Sagent Pharmaceuticals Inc (NASDAQ:SGNT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Friday. According to Zacks, “Sagent Pharmaceuticals, Inc. is a pharmaceutical company that develops and sources products with primary focus on generic injectable pharmaceuticals. Products offered by the Company cover a […]
